ENDRA Life Sciences (NDRA) Equity Ratio (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Equity Ratio data on file, last reported at 0.52 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.52, down 5.99% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.52 (down 5.99% YoY), and the FY2025 annual result was 0.59, up 1.98% from the prior year.
• Equity Ratio eased to 0.52 in Q1 2026 per NDRA's latest filing, from 0.59 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.87 in Q2 2022 and troughed at 0.09 in Q3 2025.
• A 5-year average of 0.68 and a median of 0.73 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio climbed 15.33% in 2024, then plunged 88.93% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.78 in 2022, then gained by 7.85% to 0.84 in 2023, then slumped by 31.37% to 0.58 in 2024, then advanced by 1.98% to 0.59 in 2025, then retreated by 11.38% to 0.52 in 2026.
• Business Quant data shows NDRA's Equity Ratio at 0.52 in Q1 2026, 0.59 in Q4 2025, and 0.09 in Q3 2025.